Enrichment of Deleterious Mutated Genes Involved in Ciliary Function and Histone Modification in Brain Cancer

Hyeongsun Jeong1,2, Hyo Eun Moon3,4, Seongmin Yun1

  • 1Department of Biomedical Engineering, Ulsan National Institute of Science and Technology (UNIST), Ulsan 44919, Republic of Korea.

Biomedicines
|November 25, 2023
PubMed

Insights

Patient-derived xenograft (PDX) models offer insights into brain tumor genetics. While not all mutations transfer, PDX models enrich for key brain tumor genes and pathways, proving valuable for research.

Area of Science:

  • Oncology
  • Genetics
  • Cancer Research

Background:

  • Patient-derived xenograft (PDX) models mimic original tumors for treatment identification.
  • Selection processes in xenograft environments can alter mutation profiles compared to original tumors.

Purpose of the Study:

  • To investigate mutational alterations in PDX models derived from brain tumors.
  • To assess the utility of PDX models for genetic analysis of heterogeneous brain tumors.

Main Methods:

  • Established 13 PDX models from 11 brain tumor patients.
  • Confirmed histopathological similarity between original tumors and xenografts.
  • Analyzed somatic mutations and deleteriously mutated genes in both tumor types.

Main Results:

  • Limited overlap in somatic mutations between original tumors and PDX models.
  • Enrichment of known brain tumor-related genes in PDX samples.
  • Enrichment of genes involved in cilium movement, microtubule depolymerization, and histone methylation in PDX models.

Conclusions:

  • PDX models are valuable for brain tumor research despite some mutational divergence.
  • PDX models can provide additional genetic information from heterogeneous samples like brain tumors.
  • Further research into xenograft selection mechanisms is warranted.